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Abstract
Background: The aim of this review is the critical appraisal of the current use of volumetric modulated arc therapy for
the radiation therapy management of breast cancer. Both clinical and treatment planning studies were investigated.
Material and methods: A Pubmed/MEDLINE search of the National Library of Medicine was performed to identify VMAT
and breast related articles. After a first order rejection of the irrelevant findings, the remaining articles were
grouped according to two main categories: clinical vs. planning studies and to some sub-categories (pointing
to significant technical features). Main areas of application, dosimetric and clinical findings as well as areas of
innovations were defined.
Results: A total of 131 articles were identified and of these, 67 passed a first order selection. Six studies reported clinical
results while 61 treatment dealed with treatment planning investigations. Among the innovation lines, the use of high
intensity photon beams (flattening filter free), altered fractionation schemes (simultaneous integrated boost, accelerated
partial breast irradiation, single fraction), prone positioning and modification of standard VMAT (use of dynamic
trajectories or hybrid VMAT methods) resulted among the main relevant fields of interest. Approximately 10%
of the publications reported upon respiratory gating in conjunction with VMAT.
Conclusions: The role of VMAT in the radiation treatment of breast cancer seems to be consolidated in the
in-silico arena while still limited evidence and only one phase II trial appeared in literature from the clinical
viewpoint. More clinical reports are needed to fully proove the expected dosimetric benefits demonstrated in
the planning investigations.
Keywords: Volumetric modulated arc therapy, Breast cancer, Radiotherapy
Background
The introduction of volumetric modulated arc therapy
(VMAT) in clinical practice dates back to 2008 after the
publication of the seminal work of Otto [1] which
opened the road to the implementation of VMAT
optimisation algorithms in the treatment planning sys-
tems. Since then, VMAT has been applied to almost all
possible clinical indications and a huge amount of re-
search was published. The navigation through this
plethora of articles is challenging and for this reason, the
availability of site-specific reviews might help to appraise
the state of the art and the role of VMAT in the man-
agement of the radiation oncology process. Breast cancer
is one of the most common diseases and its incidence is
increasing and will continue to increase due to early
diagnosis programs as well as to the demographic effect.
Radiotherapy is a fundamental component of the multi-
disciplinary approach to breast cancer and, depending on
several factors, many different fractionation schemes and
treatment modalities have been applied and explored with
success. The clinical use of VMAT for breast cancer is still
limited, according to published data, but it is potentially a
versatile solution, applicable to whole breast or partial
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breast treatments, conventional or altered fractionation
schemes (sequential or with simultantous integrated
boost, hypofractionated and even in single fraction). Also
from the technological point of view, interesting variants
of VMAT have been proposed and tested in-silico to
explore future possibilities.
A number of earlier published reviews [2–10] addressed
some early technical aspects of VMAT or covered the role
of VMAT in general or in other districts (lung, head and
neck, brain or SBRT). Fiorentino [6] proposed a case review
of a bilateral breast irradiation with a limited review of
literature, mostly focused on tomotherapy practice.
Aim of this review is to summarize the clinical
evidence from literature and provide an overview of the
main technical aspects and of the ongoing research
activities to consolidate the knowledge about the role of
VMAT for breast cancer treatment.
Materials and methods
Search and selection criteria
The database of the National Library of Medicine was
searched through the Pubmed/MEDLINE service. The
time search was limited to articles published after January
2008 when the article of Otto [1] was published. The
following keys were searched in all field of the article
record: “breast” and any of the following: “volumetric
modulated arc therapy”, “VMAT”, “RapidArc”, “Rapid
Arc”, “hybrid IMRT” or “hybrid-IMRT” or “hybrid
intensity modulated radiotherapy”. The resulting set of
references was further pruned after full text examination
to exclude irrelevant articles errononeously associated to
the selection criteria, duplicate records or reviews.
The time selection was set to the publication of the
original article describing the modern concept of
VMAT. This intentionally excluded the predecessors like
intensity modulated arc therapy (IMAT) and all its
variants. Similarly, the literature search exluced from the
primary keys the use of Helical Tomotherapy or of its
derived TomoDirect (TD) approach specific to breast
since the review scope was to discuss the linac-based use
of VMAT. Some Tomotherapy related articles remained
after the selection being relative to treatment planning
comparisons among different techniques. The rational
for this choice relies on two arguments. Firstly, IMAT is
certainly a predecessor of VMAT but it is a relatively old
approach, somehow limited to few institutes because the
absence of commercial and broadly available planning
system and because its complex clinical workflow.
Secondly, for Tomotherapy was excluded because of
somehow opposite reasons. Its relatively wide spread
and the existing literature is adundant. Including it in
this review it would have diluted the focus from a
specific technical approach (VMAT) to a more general
topic. The deision was not based on the belief that
different outcome should be expected when using
VMAT or Tomotherapy.
All articles were retrieved from the publisher’s archives
and full-text versions used for the data analysis.
Data analysis
All the publications were tagged according to two main
categories: treatment planning studies or clinical reports.
Within each category, sub-classes were identified ac-
cording to some relevant technical or clinical features.
Each article was allowed to belong to multiple sub-
classes but only to one main category.
The sub-classes were defined as: estimates of secondary
cancer risk (RE), accelerated partial breast irradiation or
boost use of VMAT (APBI/boost), post mastectomy
patients (PM), nodal irradiation (Nodal), bilateral breast
irradiation (BiB), respiratory gating (GAT), simultaneous
irradiation boost (SIB), single fraction (SF), use of flattening
filter free photon beams (FFF), prone positon (PP), hybrid
techniques and alternative techniques (Alt/Hybrid), opti-
misation special recommendations (Optim), helical tomo-
therapy (HT), knowledge based planning (KBP).
Results
The general selection resulted in 131 candidate articles, of
these, 64 were rejected because of several reasons. These
included: different topic within or even outside the VMAT
arena or generic studies in VMAT not focused on breast,
case reports, reviews, different techniques. Of the
remaining 67 publications, 6 belonged to the clinical
category and 61 to the treatment planning group.
Clinical studies
The six publications reporting some clinical data [11–
16] included only two studies evaluating a prospective
phase I-II trial on the use of VMAT with an accelerated
SIB fractionation. Table 1 summarizes the clinical stud-
ies in a synoptic view. Fig. 1 shows examples of achiev-
able dose distributions for uni- and bi-lateral breast
cancer treatments with simultaneous integrated boost
and VMAT.
In the original study, Scorsetti et al. [11] reported
about a 3 weeks accelerated course with 40.5Gy to the
whole breast and 48Gy to the tumor bed. Fifty patients
were treated with the RapidArc (Varian Medical
Systems, Palo Alto, USA) version of VMAT. This was an
interim report of a prospective phase I/II trial. With a
relatively short median follow-up of 12 months, the
maximum acute skin toxicity by the end of treatment
was grade 0 in 20/50 patients, Grade 1 in 32/50, Grade 2
in 0 and Grade 3 in 1/50. Three of the treated patients
were bilateral cases.
In the most recent report, De Rose et al. [12] updated
about 144 patients with at least 2 years of follow-up
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were treated according to the same protocol. These pa-
tients had a median follow up of 37 months. Four of
those patients were treated for bilateral breast cancer.
No cases of acute skin toxicity of G3 or more were ob-
served during the treatment and the highest reported
was G2, with the highest frequency (8%) during the third
week of treatment. The only case of G3 was observed at
1-month after treatment (a bilateral patient) and reco-
vered within 3 months. At 1 year the highest reported
skin toxicity was G1 (dermatitis) in 14% of the patients,
Table 1 Synoptic view of the clinical articles
Ref. # Authors Number of patients Type of treatment Median follow-up Toxicity
[11] Scorsetti et al. 50 SIB, 40.5Gy to whole breast and 48Gy
to tumor bed
12 months Skin: Max G3 (1 case)
No other toxicity
[12] De Rose et al. 144 SIB, 40.5Gy to whole breast and 48Gy
to tumor bed
37 months Skin max G3 (1 case)
Lung: max G1 (36 cases)
No other toxicity
[13] Riou et al. 9 APBI, 40 Gy in 4Gy fractions twice a day
over 5 days.
26 months Acute: Max G1
Late: Max G1
(inclusive of skin,
pneumonitis,pain,
oedema)
[14] Kim et al. 31 VMAT with nodal involvement (internal
mammary chain)
25.2 months Late max G2
No cardiac toxicity
[15] Lauche et al. HT: 31
VMAT: 42
SIB. Tumor bed: 63.2-63.8Gy; whole
breast: 52.2Gy; supraclavicular nodes:
50.4Gy; internal mammary chain nodes:
52.2Gy
Not explicitly reported.
3 months assumption
from toxicity assessment
statement
Skin: Max G3 (5% of
patients, irrespective
of technique)
Oesophagus: Max G2
(35-40%)
No lung toxicity
[16] Fiorentino et al. 16 patients SIB for synchrounous bilateral breast.
50Gy in 25 fractions to the whole breast,
60Gy to the tumor bed.
24 months No G3 of any type
Max G2 acute or late skin
toxicity
Max G1 acute dysphagia.
HT helical tomotherapy, VMAT volumetric modulated arc therapy, APBI accelerated partial breast irradiation, SIB simultaneous integrated boost
Fig. 1 Examples of achievable dose distributions for uni- and bi-lateral breast cancer VMAT treatments with VMAT
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reduced to 4% at the last followup. A correlation be-
tween late skin toxicity and the breast volume receiving
more than 36.45Gy (p < 0.0001) was reported. About
lung toxicity, only a radiographic evidence of some
change in the lung texture was recorded in 25% of the
cases with a maximum of G1 of pulmonary fibrosis. No
correlation was found against dosimetric data. No heart
toxicity was observed within the follow-up period. Breast
pain was reported in 3.5% of the patients at the last
follow-up starting from 21.6% at 6 months. Liponecrosis
was observed in 23.4% of the patients mainly localized in
the boost region. Regarding tumor control, 143 patients
had no recurrence while 1 patient developed distant me-
tastases at 39 months after radiotherapy.
Riou et al. [13] reported the use of APBI in an elderly
population. Nine patients with a median age of 74 years
were treated with 40Gy prescribed in 4Gy fractions twice
a day for 5 days. No acute or late toxicities more severe
than G2 were observed with no replapses over a median
follow-up time of 26 months. The target included the
clinical target volume, CTV, plus an isotropic margin of
18 mm to define the planning target volume, PTV. One
patient was treated for bilateral disease.
Kim et al. [14] discussed about the use of VMAT in
patient requiring internal mammary nodes irradiation
over a group of 31 patients with a median follow-up of
25.2 months. The incidence of G2 or more lung toxicity
was 3.2% while no clinically overt cardiac toxicity was
observed. Skin toxicity was not reported.
Lauche et al. [15] compared clinical data from treat-
ments performed either with linac based VMAT or HT.
In this dataset, 31 patients were treated with HT and 42
with VMAT. All the patients were treated with SIB with
different dose levels: 63.8 Gy (HT) and 63.2 Gy (VMAT)
for the tumor bed; 52.2 Gy in the breast and 50.4 Gy in
the nodal region (HT) or 52.2Gy and 49.3Gy for VMAT.
The dosimetric findings reported in the study demon-
strated a substantial equivalence of the two techniques.
Acute skin toxicity of G3 was reported in 5% of the pa-
tients regardless of the technique. No lung toxicity was
observed. Reported data was based on clinical examina-
tions up to 3 months after treatment.
Fiorentino [16] summarised the findings of their activ-
ity on bilateral breast patients. Sixteen patients received
VMAT treatment with SIB to the whole bilateral breasts.
A dose of 60.0Gy was prescribed to the tumor bed and
50Gy to the whole breast, all in 25 fractions. With a me-
dian follow-up of 24 months, no acute or late side ef-
fects more than G2 were reported (mostly skin toxicity).
No patient relapsed at the last follow-up.
Although very limited and still with short follow-up, all
the clinical data reported suggest that the use of VMAT
for the treatment of breast cancer is feasible, also in chal-
lenging situations such as bilateral targets or patients
requiring nodal irradiation. The toxicity profiles reported
are modest and compatible with the results reported with
other techniques. The need of long follow-up, particularly
for endpoints such as cardiac toxicity and second cancer
risk is obvious to demonstrate the long term outcome and
larger sets of patients would be desirable.
Treatment planning studies
The 61 studies [17–77] investigating treatment planning
issues are listed in alphabetical followed by date of publi-
cation order. Table 2 allows navigation of the references
according to the sub-classes. The message obtainable by
these experiences is quite consistent with few excep-
tions. VMAT allowed to improve or equate the level of
conformal avoidance achieved with other techniques
with a general trend towards reduction of the estimated
treatment time and monitor units. The division in sub-
classes allows to better appraise the specific messages.
 Dosimetric perspective:
Breast radiotherapy can include several different tar-
gets, depending on the stage, nodal involvement and/or
surgical intervention. These include the whole breast,
the tumor bed, the chest wall in the post-mastectomy
patients, the nodal regions (internal mammary and
supraclavicular stations), only to cite some of them. All
of these conditions were investigated comparing VMAT
against several photon based techniques. In particular,
the role of VMAT when nodal irradiation is required
was investigated by [22, 24, 52–55, 59, 63, 67, 75, 77].
The post-mastectomy situation was studied by [26, 45,
49, 59, 62, 64, 69, 71, 75, 76].
The general trend reported by the majority of the stud-
ies can be summarised in a few key conclusions: i) target
coverage, homogeneity and conformality are in general
good to optimal; ii) sparing of ipsilateral organs at risk can
be equivalent to what achievable with other techniques or
further improved; iii) the use of high intensity photon
beams, partial arcs and special field arrangements all con-
tribute to the possibility to use of VMAT in all the clinical
treatment situations; iv) VMAT, with today’s technical
implementations, is generally much simpler and faster to
deliver compared to IMRT for the clinical situations en-
countered with breast cancer.
Where most of the planning studies compared different
linac-based techinques, an interesting sub-class of studies
presented comparisons of VMAT with respect to either
HT or its “fixed” mode, TomoDirect (TD) [32–34, 49, 58].
Also the clinical study from Lauche [15] contributes to
the discussion. Qi [58] suggested that VMAT or HT re-
sulted dosimetrically preferable to IMRT or TD but with-
out definitive preference. Nichols [49] studied 15 patients
and compared VMAT to HT. Both techniques provided
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clinically acceptable plans with different features (VMAT
improved conformality and organs sparing at lower doses
while HT results in better homogeneity and better organs
sparing at high doses). Authors concluded stating that
both techniques were clinically used in their institute.
Haciislamoglu [32, 33] showed with two studies on 15 and
10 patients that both VMAT and HT were dosimetrically
comparable with HT slightly improving the medium-high
dose sparing for the organs at risk but increasing the low
dose spread to the healthy tissues. Han [34] in their risk
estimation studies (discussed below) concluded that the
TD approach resulted preferable to the others. All in all,
including the clinical reports, no study proved an absolute
differential benefit from one technique or the other sug-
gesting a fair equivalence between the two approaches
from a dosimetric perspective.
To conclude this section, it is worth to mention two
negative studies. Badakhsi [20] concluded that the hy-
pothesis of equivalence between VMAT and IMRT was
negated by the in-silico data from 12 patients. This was
observed for both target coverage and organs at risk
sparing, especially for low dose levels (V2Gy, V5Gy and
V10Gy) and for mean doses.
Similarly, Jin [36] demonstrated on 20 left-sided pa-
tients that VMAT was inferior to IMRT in terms of tar-
get coverage and low-dose organs at risk sparing and did
not recommended VMAT for these patients.
 Secondary cancer and risk estimates:
Six publications were tagged within this sub-class
[17, 25, 34, 37, 41, 69].
Abo-Maydan [17] suggested that VMAT might have a
higher risk of secondary cancer induction compared to
conformal or tangential IMRT. Data are based on 10
patients.
Dobler [25] summarized for 6 patients the excess abso-
lute risk for second cancer for right-sided breast patients
to be treated with SIB and either flattened (FF) or Unflat-
tened (FFF) photon beams. Their data showed a significant
reduction of the risk to the contralateral and peripheral
organs when FFF beams were used in conjunction with a
tangential arcs approach. The risk reduction amounted to
~25-29% or 44-58% if tangential FFF VMAT was com-
pared to tangential FF or full arc or IMRT approaches.
Han [34] compared for 10 patients five different ap-
proaches (from conformal therapy to HT in the TD
form) and the lifetime attributable risk (LAR) resulted
the worst for VMAT while TD scored best for most of
the organs considered in the analysis. The main concern
about this study is that the linac-based plans were all
computed using a very old version of the VMAT soft-
ware, basically the first generation of it, and no evidence
of any strategy for the minimisation of the uninvolved
contralateral organs was provided.
Johansen [37] computed in 8 patients the estimated
excess relative risk (ERR) with linear and non linear
models for conformal RT, IMRT and VMAT data. The
VMAT plans resulted with an intermediate non-linear
ERR (0.33 compared to 0.31 for conformal and 0.39 for
IMRT), with no statistically significant difference.
Lee [41] compared conformal, IMRT and VMAT ap-
proaches measuring phantom doses with photoluminescent
detectors and demonstrated that the LAR of secondary
Table 2 Navigation view of the planning investigations (not included the clinical references approaching some of the sub-classes)
Sub-class References
Risk analysis [17, 25, 34, 37, 41, 69]
Nodal involvement [22, 24, 52–55, 59, 63, 67, 75, 77]
Post Mastectomy [26, 45, 49, 59, 62, 64, 69, 71, 75, 76]
SIB [19, 21, 23, 25, 29, 38, 47, 48, 50, 63, 67, 70]
APBI/Boost [18, 27, 28, 42, 56, 57, 60, 62]
Bilateral breast [29, 50]
Prone position [42, 73, 74]
Single fraction [23, 73]
Flattening filter free beams [21, 25, 40, 47, 61, 62]
Planning strategies [22, 30, 31, 48, 53, 66, 68, 74]
Hybrid technique [19, 21, 35, 38, 43, 61]
Alternative approaches [28, 39, 42, 45, 46, 56, 60]
Respiratory Gating [27, 35, 51, 52, 55, 64]
Comparison with helical tomotherapy [32–34, 49, 58]
Other general [20, 36, 39, 43, 44, 46, 65, 72]
APBI accelerated partial breast irradiation, SIB simultaneous integrated boost
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malignancies was lowest for conformal RT and maximal for
IMRT with VMAT falling inbetween the two.
Wang [69] computed for 30 patients the tumor control
and normal tissue complication probabilities for con-
formal, fixed field tangential IMRT and single arc
VMAT. Their results suggested that TCP and NTCP for
target volume and left lung, respectively, did not show
significant differences. Heart NTCP ranged from 3 to 7%
among techniques (5% for VMAT).
With the exception of [37] and to some extent [69],
the studies demonstrated a general trend towards some-
how higher risk of secondary cancer induction or life-
time risk if VMAT is applied compared to conformal
therapy or tangential IMRT. Unfortunately no study of
secondary risk is available for VMAT data planned with
highly intensive OAR sparing methods and compactified
dose distributions as would be available today. Long
term clinical data and better designed in silico studies
on large cohorts of patients would be needed.
 Altered fractionations:
The use of VMAT for APBI or for the boost treatment
was reported in 7 articles [18, 27, 28, 42, 57, 60, 62, 65]
plus the previously mentioned clinical study from Riou
et al. [13]. Since its early days, VMAT was compared
against electron, photons and even protons for the treat-
ment of the boost volume. Toscas [65], on 14 patients,
seeded the field and demonstrated that VMAT (or
IMRT) provided the best coverage of the targed, com-
patible with protons while enabling the maximal sparing
of the dose to the skin (5.4Gy in average compared to
7.2Gy for electrons or 5.8 to 7.5 for all other techniques
with photons or protons). The concept was naturally ex-
tended to APBI [13, 27, 28, 42, 56, 60]. Popescu [56]
interestingly proposed to combine the VMAT approach
to the simultaneous rotation of the couch to further
boost the sparing of the healthy tissues. Riou’s study [13]
is the only one reporting about clinical treatments.
Charaghvandi [23] and Yoo [73] investigated the use
of VMAT for single pre-operative fraction delivery. In
the first study [23], the tumour of 20 patients with early
stage cancer was contoured on a pre-operative MR and
contrast-enhanced CT scans. A single dose of 15Gy was
prescribed to the clinical target volume and 20Gy to the
gross tumor volume. The VMAT plans were compared
against interstitial multicatheter brachytherapy. The au-
thors conclude that both approaches could be dosimetri-
cally appropriate but with a preference to VMAT due to
the target overdosage inherent to the brachytherapy
technology. In the second investigation [73], the authors
applied different techniques (conformal, coplanar and
non-coplanar IMRT and VMAT) to 16 patients. The
dose prescription was 15Gy to the clinical and 18Gy to
the gross target volumes. Though VMAT resulted the
potentially fastest technique (7 min of beam on time
compared to 8.3-11.0 for the others), the authors found
a benefit of IMRT in terms of target homogeneity and
conformality as well as for skin sparing.
The SIB approach was discussed at various levels in
[19, 21, 23, 25, 29, 38, 47, 48, 50, 63, 67, 70].
 Altered patient positioning and bilateral breast:
Three studies investigated the case of prone position-
ing [42, 73, 74] while two planning studies addressed the
bilateral breast problem [29, 50] in addition to the clin-
ical studies [11–13, 16].
The prone positioning has been appraised by some au-
thors in conjunction with other innovative aspects. Yoo
[73] proposed it for the case of single fraction delivery in
partial breast treatments. Sixteen patients were simu-
lated and, compared to other techniques (conformal or
fixed field IMRT), VMAT offered the shortest estimated
treatment delivery time and better sparing of normal tis-
sue except skin, but yielded less dose conformity and
homogeneity within target. For this latter reason, au-
thors concluded that their preference went to fixed field
IMRT. Yu [74] studied 10 patients positioned prone to
demonstrate the feasibility of small-arc VMAT and con-
cluded that it was possible to improve conformity,
homogeneity and dose to organs at risk. Liang [42] in-
vestigated for 10 patients in prone position the possibil-
ity to use nonisocentric trajectories to deliver modulated
arcs for APBI. They concluded that a marked reduction
of the irradiation of the uninvolved breast tissue was
achievable with this approach.
The number of synchronous bilateral breast patients
in routine clinical practice is not too large. For this rea-
son, offering an optimal treatment to these patients
might require advanced planning skills. Nicolini [50]
published in 2009 the seminal work in this area simulat-
ing 10 patients. A SIB fractionation (with different dose
levels between left and right breasts if needed) was ap-
plied. With a technology still in its infancy, authors
showed that VMAT reduced the V20Gy below 10% and
MLD < 10Gy and the mean dose to heart to 6Gy (com-
pared to 7.4 for IMRT). This study proved the feasibility
of VMAT for bilateral breast treatments, with a single
isocenter and the use of asymmetric arcs. The clinical
practice reported above reflected this initial pivotal pro-
ject. More recently, Fogliata [29], in the framework of a
knowledge based planning automation project, showed
that models developed to optimise unilateral breast
treatment, could be applied successefully, with multi-
centric validation, also to bilateral breast targets. This
further simplifies the technical burden connected to the
relatively rare incidence of these cases.
Cozzi et al. Radiation Oncology  (2017) 12:200 Page 6 of 12
 Alternative techniques or hybrid techniques:
Hybrid techniques, mixing IMRT with fixed fields and
VMAT were reported in 6 studies [19, 21, 35, 38, 43, 61].
The basic rationale of hybrid techniques is to mix fixed
beam IMRT to VMAT with the aim of obtaining a benefit
from both techniques and mitigate their eventual pitfalls.
Aly [19] proposed the use of IMRT fields for the whole
breast and VMAT for the boost and studied the method on
12 patients with SIB fractionation. The hybrid VMAT
approach outperformed the full VMAT method for both
ipsilateral lung and heart (in left-sided patients) dose spar-
ing. Bahrainy [21] reported about an in-silico investigation
on 10 patients (left-sided) where two tangential IMRT fields
were combined to one VMAT arc. The study was
performed for both FF and FFF photon beams. Authors
reported that the combination of their hybrid approach to
the FFF technology enabled a substantial reduction of treat-
ment time and improved dosimetric potential, all suggest-
ing the applicability of the method for hypofractionated
dose schemes.
Other more forward-looking alternative technical
approaches were investigated in 7 articles [28, 39, 42, 45,
46, 56, 60]. In most of these studies, not-clinically available
strategies were tested. These included non-isocentric
trajectories, simultaneous couch and gantry rotations or
burst technique (a kind of “step-and-shoot” VMAT where
dose is delivered with static gantry at fixed intervals during
arc rotation). Ma [46], in opposition to the mainstream of
increased dose rate with FFF beams, analyzed with Monte
Carlo simulations, the possibility to deliver kind-of pulsed
VMAT with low dose rates (0.2Gy/arc with 3 min of inter-
val between arcs to achieve an effective dose rate of
0.67Gy/min) All these methods require dedicated and spe-
cialised planning and delivery technology not commonly
and not clinically available today.
 Respiratory Gating:
In six publications [27, 35, 51, 52, 55, 64], the use of
respiratory gating was specifically addressed. The first
article was published by Nicolini [51] with a pre-clinical
investigation showing a high reliability of the delivery
systems to the beam hold required by the gating process,
even when high frequency interruptions (free breathing
rather than breath hold) were simulated. Among the
most recent data, Pham [55] demonstrated that, com-
pared to gated IMRT, gated VMAT might contribute to
further reduce mean heart dose in selected patients. On
the contrary, Jeulink [35] showed that, under free
breathing conditions, hybrid IMRT approaches might be
preferable to VMAT in breast treatments.
 Flattening filter free photons:
The use of high intensity photon beams was addressed
in 6 studies [21, 25, 40, 47, 61, 62] plus the two clinical
reports from the Humanitas Cancer Center group [11,
12]. The treatment of the whole breast or of the chest
wall, as well as the use of conventional or of SIB frac-
tionation schemes were appraised. In all cases, the data
suggested a potential benefit in the use of FFF beams
particularly for the SIB schemes. Even in the case of
chest wall irradiation [40, 62], the use of FFF could con-
tribute to minimize the dose to the contralateral organs
as a consequence of reduced scatter.
 Special optimisation suggestions or guidelines
Mancosu et al. [48] discussed the use of automatic
constraints on the monitor units showing a possible cor-
relation between the increase of MU and the increase of
OAR involvement while modest impact was observed on
target coverage. Nicolini et al. [31] investigated and pro-
posed a practical solution to account for the “missing
fluence” outside the body outline in the absence of auto-
mated “skin flash” tools in the optimisation of VMAT
plans. The methodology proposed should compensate
for potential underdosage of the most superficial region
due to tissue expansion or displacement of the body
(breathing, movments, oedema or other mechanisms).
Originally, VMAT was developed and tested aiming to
use full arcs, one or multiple. In the case of breast treat-
ments, this might result dosimetrically sub-optimal
(mainly due to the involvement of the contralateral struc-
tures but also of the ipsilateral lung and heart for the left-
sided patients)) if fluence cannot completely go down to
zero during full arc treatments because of technical con-
straints in the optimization process. The use of split or
short arcs or the use of avoidance sectors, mimicking the
tangential beam concept, was investigated by several
groups [22, 30, 53, 66, 68, 74]. All significantly reduced
the dose to all the organs at risk while preserving adequate
target coverage. Fogliata [30] showed that, either using
partial arcs or using “avoidance” sectors (basically drop-
ping the dose rate to 0 within sub-arcs sectors, dosimetri-
cally equivalent to the use of split arcs but technically
easier), the mean dose to the heart was reduced by 51%,
12% for the ipsilateral lung, by 81% for the contralateral
lung and by 73% for the contralateral breast compared to
full arcs. All differences were significant with p < 0.001.
The absolute mean dose to the heart (left treatments) was
dropped to <2Gy; the mean dose to the contralateral lung
as well as to the contralateral breast to ~0.6Gy for hypo-
fractionated treatments of 40.05Gy in 15 fractions.
Discussion
Despite VMAT having been introduced in clinical prac-
tice approximately 10 years ago and despite its wide
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application in many different clinical indications [2–10],
its application to the treatment of breast cancer is still
limited. This is reflected in the paucity of published re-
ports on clinical experiences.
Clinical studies
Concering the clinical reports [11–16], few general fac-
tors can be outlined. The short follow-up of these stud-
ies limits the evidence mostly to the area of acute
toxicity which was reported to be very modest by all au-
thors. Late toxicity and control (up to 2 years) data are
promising but of course cannot be conclusive. The main
limit consisted in the small sample of patients reported.
The exception comes from the only one prospective
phase I/II trial has been reported so far [11, 12], with
the latest interim analysis reporting, data of 144 treated
patients with a minimum follow-up of 2 years. This is
the largest sample so far. This protocol combined also
two important clinical themes: the use of SIB fraction-
ation and accelerated treatments, uni- or bilateral treat-
ments. The data from all studies are basically consistent
and encouraging. For example, Kim et al. [14] and
Lauche et al. [15] demonstrated, although with smaller
samples, the possibility to achieve good results for the
lymphnodal irradiation with VMAT, a result quite chal-
lenging with other techniques. Of course larger cohorts,
longer follow-up and more structured trials are needed
in this respect.
It is nevertheless reasonable to believe that the actual
clinical adoption of VMAT for breast is wider.
Ttreatment planning studies
the wide adoption of VMAT for breast, might be extrap-
olated from the extensive literature published about in-
silico investigations covering basically all technical and
clinical areas [11–77]. From the comprehensive appraisal
of this category and its sub-classes, a number of global
messages can be derived.
Firstly, and unfortunately, also the merely planning
studies are frequently limited by the small number of pa-
tients included. With the exception of the knowledge
based planning study [29] where in total more than 200
patients were considered between training and validation
phases, the typical sample size in the planning investiga-
tions ranges from few units to some tens, unbalanced to-
wards the lower limit. Although the scope of in-silico
studies is the proof of the principle, these investigations
might benefit from a stronger accounting for the inter-
patient variability with more statistical power.
Dosimetric perspective, altered fractionation:, flattening
filter free photons: Beside this limitation, the evidence de-
rived from these studies suggests that, from a dosimetric,
a deliverability and a logistics point of view, VMAT might
be considered for the treatment of the whole breast or for
the post mastectomy cases as well as for the patients with
or without nodal involvement; also partial breast irradi-
ation was considered and proved to be feasible. Altered
fractionation schemes (like SIB, hypofractionation or even
single fraction) could be effectively proposed in addition
to conventional fractionation. This is a really appealing
possibility in general, consistent with many recent recom-
mendations and applicable, in the extreme modalities, to
well selected groups of patients. The use of advanced pho-
ton beams (the high intensity or flattening filter free
beams) was tested and the results suggest that improved
sparing of organs at risk, particularly at low doses can be
achieved while facilitating delivery of multi-level doses to
the targets.
Special optimisation suggestions or guidelines
Technical recommendations on special optimisation
strategies were reported. From these, the use of multiple
partial arcs or the use of hybrid VMAT or the combin-
ation of both can be considered today as a possible strat-
egy for breast. One of the main topics of breast
irradiation is the management of respiratory induced
motion. Gated delivery was investigated with success
and, as for IMRT and conventional treatments [78], the
use of deep inspiration breath hold seems to be the most
appropriate approach. One unsolved issue is the rele-
vance of prone compared to supine positioning. Not
enough literature was published in this area to draw any
conclusion or recommendation. We have not addressed
in detail a comparison of the various technical aspects of
the arc arrangements (number and length of the arcs,
collimator angles, couch rotations) since this would be
challenging in a synoptic view doe to the excessive num-
ber of variants. Readers are referred to the original pub-
lications for these details.
Secondary cancer and risk estimates
While in conclusion from a dosimetric/logistics point of
view VMAT seems to be comparable with other modu-
lated strategies, two delicate issues remain for all isotropic
treatment strategies, trading reduced volumes treated to
high doses with larger volumes treated to lower doses.
One is the risk of secondary malignancy induction in a
group of patients with a general long life expectancy.
While modelling currently suggests a potential slight in-
crease in second cancer risk with IMRT/VMAT, recent
clinical data in prostate cancer [79] and preclinical data
[80, 81] suggest that the opposite might be the case be-
cause the second-cancer-risk/dose relationship may actu-
ally be supralinear with animal data actually suggesting a
threshold-like-dose of >25 Gy for single dose exposure.
Moreover, a topical systematic review on dose-response
relationships for solid cancers induction in humans
showed that the excess risk per Gy is considerably lower
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after fractionated radiation therapy than after acute lower-
dose exposure experienced by the Japanese atomic bomb
survivors, in the range of 5-fold to 10-fold lower, and that
at higher fractionated doses it is unlikely that the risk
would decrease (with the exception of thyroid cancer) [82].
Old models used for secondary cancer risk estimates may
have not included these important changes, and would
generally end up in a theoretically negative impact of
VMAT in comparison with 3D-CRT. Recent modelling
studies on breast cancer risk associated to mediastinal
VMAT in Hodgkin’s lymphoma did not show any add-
itional risk in comparison with 3D-CRT when appropriate
dose constraints are used [83]. The hypothesis of reduced
second cancer risk with modulated techniques has been
outlined conceptually recently [84].
Cardiac toxicity
The second issue is cardiac toxicity. Meaningful epi-
demiological data regarding cardiac toxity from radio-
therapy exist only for tangential radiotherapy. As it has
recently been pointed out, these data cannot be used to
estimate risk from dose distributions with a different
character using an appropriate biological model [85] a
quasi-threshold might exist also in this area and recent
imaging data from clinical series [86] have in fact sug-
gested that such a threshold (20-30 Gy) as predicted by
the models may exist, again resulting in a favourable
outcome with modulated techniques such as VMAT.
In summary, regarding those two issues,in the absence
of strong positive or negative evidence, some caution in
the selection of patients is advisable. Simple cases with
no heart exposure and minimal lung exposure upon tan-
gent treatments, might not benefit from VMAT while
the more complex situations, due to anatomy or dose
prescription or other concomitant reasons, could likely
benefit in terms of clinical estimates from VMAT. The
latter group, could include large breasts, highly concave
chest walls as anatomical features and particularly the
treatments that include draining lymph nodes.
Conclusions
The role of VMAT in the radiation treatment of breast
cancer seems to be consolidated in the in-silico arena
while still limited evidence and only one phase II trial
appeared in literature from the clinical viewpoint. More
clinical reports are needed to fully proove the expected
dosimetric benefits demonstrated in the planning
investigations.
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